Search

659 Result(s)
Sort by

digital_leader_award_2020

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Netherton Syndrome

Netherton Syndrome

Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
STOP Rabies: moving towards elimination

STOP Rabies: moving towards elimination

Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Global mobility

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Our-position

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
opening-solids-launch-fabrik

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Green Chemistry

Green Chemistry

Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Sabine Reinig

Sabine Reinig

For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
clinical_collaboration_with_Mirati

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
FDA-CRL-T1D

FDA-CRL-T1D

US FDA issues complete response letter for treatment of adults with type 1 diabetes
The METAmorphosis

The METAmorphosis

At Boehringer Ingelheim’s META offices in the Middle East, Turkey and Africa all offices in the region are already free of single-use plastic.
How do our donations for Ukraine help?

How do our donations for Ukraine help?

The war in Ukraine continues to cause suffering and hardship. The Polish and the German Red Cross – also supported by donations from us – help to the best of their ability.
Expectations towards our business partners

Expectations towards our business partners

We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.